Understanding how certain immune cells contribute to multiple sclerosis
Official title: A TCF1:Glucocorticoid regulatory circuit controls IL-23-driven Th17 pathogenicity
Funded at Brigham and Women's Hospital · NIH-11011462 · Data updated 2026-11-12
This study is looking at how certain immune cells called Th17 cells can change and cause inflammation in multiple sclerosis, with the hope of finding new ways to treat the condition and help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | February 1, 2023 |
| Project end | January 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $501,978 |
| NIH project number | 5R01AI176341-03 |
| Project ID | NIH-11011462 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with multiple sclerosis or those at risk due to genetic factors.
✕Less likely to help
Patients with other autoimmune conditions unrelated to Th17 cell activity may not benefit from this research.
What this research studies
This research investigates the role of specific immune cells, known as Th17 cells, in the development of multiple sclerosis (MS). It focuses on understanding how these cells can switch from a non-pathogenic state to a pathogenic state that drives inflammation in the central nervous system. By studying genetic factors and signaling pathways involved in this process, the research aims to uncover new therapeutic targets for MS treatment. Patients may benefit from insights that could lead to innovative therapies aimed at preventing or reducing the severity of MS.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that better manage or prevent multiple sclerosis.
How similar studies have gone: Previous research has shown promising results in understanding Th17 cell biology, suggesting that this approach could yield valuable insights for MS treatment.
Where this research is happening
-
Brigham and Women's Hospital
Boston, United States Active
Researchers
- Principal investigator: Anderson, Ana C — Brigham and Women's Hospital
- Study coordinator: Anderson, Ana C
Related research
Other NIH-funded projects on the same topics.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
Statins to Prevent Cancer-Associated Blood Clots in Cancer Patients
A large study will test whether taking rosuvastatin every day for a year can lower the chance of dangerous blood clots in people with cancer, without raising the risk of bleeding.
-
Preterm infant body composition and early-life health after NICU stay
This grant studies how body composition in very preterm babies relates to later brain development and risk of obesity or diabetes, with findings meant to improve care from NICU through early childhood.
-
Rapid Emergency Skills for Prehospital Optimization and Delivery (RESPOND) for Guatemala
A lightweight, AI-enabled prehospital training and triage program helps volunteer firefighters in Guatemala deliver faster, better care to trauma patients.
-
Rapid Emergency Skills for Prehospital Optimization and Notification in Guatemala
A mobile, AI-powered training and triage program helps volunteer emergency responders in Guatemala provide faster, safer trauma care and notify hospitals more quickly.
-
Understanding antibiotic allergy to improve care for patients
Scientists are testing new ideas to understand why some people develop severe allergic reactions to antibiotics and how to prevent or treat them.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.